## Clinical Oversight Review Board (CORB) Criteria for Prescribing

## Velaglucerase alfa (Vpriv)

## Notes:

- Quantity Limits: No
- ^ Treatment failure is defined as failure to meet clinical goals (e.g., persistent anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly)


Formulary **velaglucerase alfa (Vpriv)** requires a clinical review. Appropriateness of therapy will be based on the following criteria:

## Initiation (new start) criteria and criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously:

- Prescriber is a geneticist.
- Patient has a diagnosis of Type 1 Gaucher disease
- Patient has signs and symptoms of symptomatic disease, including: anemia, thrombocytopenia, skeletal disease, or visceromegaly (*liver or spleen* enlargement)
- Patient has failed<sup>^</sup> treatment with taliglucerase alfa (Elelyso) or patient has an allergy or intolerance to taliglucerase alfa (Elelyso).

kp.org

Revised: 08/08/24 Effective: 10/17/24





All plans offered and underwritten by